Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

How We Fixed Nitrosamine, NDSRI, and Mutagenic Impurity Compliance Gaps

Managing impurities becomes complex when a drug product involves a mutagenic impurity, an NDSRI, and a nitrosamine.

Teams must determine which Mutagenic Daily Dose (MDD) or Acceptable Intake (AI) applies. They must also assess whether AIMS testing changes the impurity classification.

Meanwhile, market-specific requirements can affect testing decisions. CMC, toxicology, analytical, regulatory, QA, and supply-chain teams must remain aligned.

The challenge grows because teams must interpret ICH M7, EMA nitrosamine Q&A, FDA policies, and CPCA categories together. Yet no single regulatory document explains how all these impurity frameworks should interact.

In this case, our team organized these overlapping requirements into a unified, inspection-ready impurity decision framework.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • Overlapping impurity frameworks:Mutagenic impurities use ICH M7 limits, nitrosamines use strict AIs, and NDSRIs follow CPCA Categories 1–5.
  • Selecting the correct acceptable intake: The lowest, most conservative limit applies. For example, if the limits are 1.5 µg/day, 600 ng/day, and 100 ng/day, the final limit is 100 ng/day.
  • Misinterpreting AIMS testing: A negative AIMS result may support some non-nitrosamine mutagens. However, it does not remove nitrosamine classification or override nitrosamine toxicology.
  • Different market expectations: FDA often expects confirmatory testing. EMA may accept strong scientific justification, while ANVISA tests more often and PMDA expects strong NDSRI evidence.
  • Fragmented impurity governance: Separate interpretations and tracking methods created inconsistent impurity assessments across products, sites, and markets.

Zamann Pharma Support’s Approach

  • Apply the lowest acceptable intake: Use the most conservative limit. Nitrosamine AI takes priority, followed by NDSRI CPCA limits and then mutagenic impurity MDDs. The limits are not combined or averaged.
  • Define clear AIMS logic: AIMS can support assessment of some non-nitrosamine mutagens. However, it does not override nitrosamine classification.
  • Build one impurity decision tree: Use one workflow for structural alerts, NDSRI triggers, nitrosamine pathways, CPCA categories, and testing decisions.
  • Centralize market requirements: A global Market Rules Matrix helps teams manage market-specific expectations and avoid conflicting regulatory decisions.
  • Strengthen cross-functional governance: Align toxicology, QA, regulatory, CMC, and analytical teams through shared trackers, dashboards, and consistent workflows. consistent workflows.

Results Achieved

  • Six products required reformulation: A company treated a negative AIMS test as removing a nitrosamine classification. FDA disagreed, and six marketed products required reformulation.
  • More than 80 products required re-evaluation: One site used the ICH M7 limit instead of the nitrosamine limit. EMA identified the issue during renewal, requiring more than 80 products to be reassessed.
  • Approval was delayed by 10 months: The US submission used CPCA Category 1, while the EU submission used Category 3. Regulators requested justification for the inconsistency, delaying approval by 10 months.
  • Three batches were rejected: One company tracked mutagenic impurities separately from nitrosamines. Teams lost alignment, laboratories tested the wrong target, and three batches were rejected.
Laboratory
Pharmaceutical quality team reviewing nitrosamines risk assessment documentation aligned with ICH M7 and current regulatory compliance requirements
Services

Nitrosamines Regulatory Compliance

We assist pharmaceutical teams in assessing and managing nitrosamines risks by aligning processes with ICH M7 requirements and current regulatory expectations.

Read More

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. Which acceptable intake applies when mutagenic impurities, NDSRIs, and nitrosamines overlap?

Use the lowest, most conservative applicable intake. For example, if the limits are 1.5 µg/day, 600 ng/day, and 100 ng/day, the controlling limit is 100 ng/day.

 

 

2. Can a negative AIMS test remove a nitrosamine or NDSRI from regulatory control?

No. The source states that AIMS may support reclassification of some non-nitrosamine mutagens, but it does not remove nitrosamine classification or override nitrosamine toxicology.

3. When is confirmatory nitrosamine testing expected by FDA and EMA?

Testing or assessment is needed when nitrosamine formation is plausible, NDSRI pathways exist, CPCA indicates carcinogenic potential, or API synthesis enables nitrosation. FDA often expects confirmatory testing, while EMA may accept a strong scientific rationale without testing.